Aerie reports financial results for first quarter of 2014

Aerie Pharmaceuticals reported first quarter earnings of $65.1 million in cash, cash equivalents and short-term investments, according to a press release.This revenue is expected to fund phase 3 development of Rhopressa, a once-daily eye drop targeting the trabecular meshwork, through NDA filing, as well as development through phase 2b trial completion and future phase 3 preparations of Roclatan, a once-daily glaucoma eye drop.

Full Story →